Le Lézard
Classified in: Health
Subject: SVY

Endocrine Testing Market is Projected to Rise to US$12.8 bn by 2023, Says TMR


ALBANY, New York, September 19, 2018 /PRNewswire/ --

According to TMR, the global endocrine testing market will exhibit a CAGR of 8.5% between 2015 and 2023. At this pace, the market will reach US$12.8 bn by the end of 2023. Among end users, the market is likely to witness the highest demand from commercial laboratories segment. The rising trend of outsourcing various testing procedures will fuel the demand for endocrine testing from commercial laboratories. Regionally, North America is forecast to contribute the highest revenue towards the global endocrine testing market. However, in the coming years, the Asia Pacific market is expected to rise at a stellar CAGR and offer lucrative prospects for companies.

     (Logo: https://mma.prnewswire.com/media/664869/Transparency_Market_Research_Logo.jpg )

Rising Incidence of Chronic Diseases to Fuel Demand for Endocrine Testing 

The demand for endocrine testing is expected to rise in response to the increasing incidence of diabetes and obesity around the world. A key point to note here is that monitoring the endocrine hormone is vital for the management of diabetes. This as per TMR is a crucial factor driving the market. Additionally, the rising incidence of cardiovascular diseases, cancer, and other ailments will fuel the demand for endocrine testing in the coming years.

Get PDF Brochure for Research Insights at https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1645

High Price of Endocrine Testing May Hinder Market's Trajectory 

On the downside, the high price of advanced endocrine testing technologies has made them unaffordable across various developing and underdeveloped regions. This is a key factor hampering the market's growth rate. Besides this, limited awareness about healthcare facilities among people living in low-income region will hinder the market's trajectory to an extent.

Nonetheless, recent advancements in assays and various methods used for endocrine testing will enable growth in the market in the coming years. Furthermore, the market is likely to benefit from recent improvements in diagnostic technologies such as liquid chromatography-mass spectrometry (LC-MS). Spurred by these factors, the global endocrine testing market will exhibit steady growth over the course of the forecast period.

Request a Sample of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1645

The global endocrine testing market exhibits a fairly oligopolistic vendor landscape, with the top five companies occupying nearly 90% of the overall market in 2014, finds Transparency Market Research (TMR) in a new study. According to the report, DiaSorin, Abbott Laboratories, Siemens Healthineers, Agilent Technologies, and F. Hoffmann-La Roche AG emerged dominant in the global endocrine testing market in 2014. Among these companies, Roche led the overall market in the same year. In order to maintain a strong foothold in the global market, the leading companies are developing next-generation sequencing platforms, advanced lab automation systems, analyzers, and endocrine test kit.

Request a Custom Report at https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=1645

Currently, the market is witnessing intense competition among the leading companies and it is expected to get fiercer in the coming years. In order to steal a march against competition, the market players are likely to invest in expanding their product portfolio and developing innovative technologies. These strategies are likely to have positive influence on the overall market.

Browse Press Release: https://www.transparencymarketresearch.com/pressrelease/endocrine-testing-market.htm

This review is based on a TMR report, titled  "Endocrine Testing Market (Test - Estradiol (E2) Test, Follicle Stimulating Hormone (FSH) Test, Human Chorionic Gonadotropin (hCG) Test, Luteinizing Hormone (LH) Test, Dehydroepiandrosterone sulfate (DHEAS) Test, Progesterone Test, Testosterone Test, Thyroid Stimulating Hormone (TSH) Test, Prolactin Test, Cortisol Test, Insulin Test Gastrin, Thymosin Secretin; Diagnostic Technology - Tandem Mass spectrometry, Immunoassay Technologies (Enzyme immunoassays and Radioimmunoassays (RIA)), Monoclonal and Polyclonal Antibody Technologies, Sensor Technologies (Electrochemical and Biosensors), Clinical Chemistry Technologies, and Liquid Chromatography-Mass Spectrometry (LC-MS); End User - Hospitals, Commercial Laboratories, Ambulatory Care Centers, Home Based Tests, and Physician Offices) - Global Industry Analysis, Size, Share, Growth Trends and Forecast, 2015 - 2023." 

Popular Research Reports by TMR: 


https://www.transparencymarketresearch.com/chemiluminescence-immunoassay-analyzers-market.html


https://www.transparencymarketresearch.com/fertility-testing-devices-market.html

About Us 

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company's exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR's experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

TMR's data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.


Contact

Mr. Rohit Bhisey
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: [email protected]

Website: http://www.transparencymarketresearch.com

Research Blog: https://theglobalhealthnews.com/


SOURCE Transparency Market Research


These press releases may also interest you

at 07:05
Volastra Therapeutics, a clinical-stage biotechnology company, today announced it has dosed the first patient in its Phase Ib clinical trial evaluating sovilnesib in patients with platinum-resistant or refractory high-grade serous ovarian cancer...

at 07:03
Prolerity Clinical Research ("Prolerity), a clinical research site network and an AHP portfolio company, announced today that it has appointed Drew Domescik as Chief Financial Officer. Prolerity currently owns and operates 11 research sites across...

at 07:02
Il Granaio delle Idee (IGDI), an innovative international developer and provider of clean label baking ingredients, and Ginkgo Bioworks , which is building the leading platform for cell programming and biosecurity, today announced a new...

at 07:00
via NewMediaWire -- Marizyme, Inc. ("Marizyme", OTCQB: MRZM) announces today a Co-Development Agreement (the "Agreement") with Qualigen Therapeutics, Inc. ("Qualigen")  to advance the commercialization of Marizyme's first-in-class FDA cleared...

at 07:00
Nobias Therapeutics, a biotechnology company pioneering artificial intelligence (AI)-based deep phenotyping techniques to...

at 07:00
Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. , today announced that it will present preliminary data from its Phase 1 study of BMC128, in combination...



News published on and distributed by: